Performance of the Rheumatoid Arthritis Disease Activity Index in the Assessment of Disease Activity in Rheumatoid Arthritis-Findings From the REAL Study.

Autor:	Ramon Haddad PA; From the Rheumatology Unit., Vargas-Santos AB; From the Rheumatology Unit., Silva Freire Coutinho E; Institute of Social Medicine, Department of Epidemiology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro., Rocha Pereira L; Institute of Social Medicine, Department of Epidemiology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro., Henrique da Mota LM; Disciplina de Reumatologia, Faculdade de Medicina, Universidade de Brasília., Pires de Albuquerque C; Serviço de Reumatologia, Universidade de Brasília, Brasília., Brandão de Resende Guimarães MF; Serviço de Reumatologia, Hospital das Clínicas da Universidade Federal de Minas Gerais, Belo Horizonte., Louzada-Júnior P; Disciplina de Reumatologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto., Rossi Bonfiglioli K; Disciplina de Reumatologia, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo., de Carvalho Sacilotto N; Serviço de Reumatologia, Hospital do Servidor Público Estadual de São Paulo, Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo., Radominski SC; Disciplina de Reumatologia, Faculdade de Medicina da Universidade Federal do Paraná, Curitiba., Aliel Vigano Pugliesi A; Serviço de Reumatologia, Universidade Estadual de Campinas, Campinas., Lobato da Cunha Sauma MF; Disciplina de Reumatologia, Faculdade de Medicina, Universidade Federal do Pará, Belém., Alves Pereira I; Disciplina de Reumatologia, Universidade do Sul de Santa Catarina, Palhoça., Viegas Brenol C; Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre., da Rocha Castelar-Pinheiro G; Disciplina de Reumatologia, Departamento de Medicina Interna, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
Jazyk:	angličtina
Zdroj:	Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases [J Clin Rheumatol] 2022 Jun 01; Vol. 28 (4), pp. 206-211. Date of Electronic Publication: 2022 Mar 22.
DOI:	10.1097/RHU.0000000000001834
Abstrakt:	Background/objective: Although telemedicine use has been under discussion for decades, this topic has gained unprecedented importance during the COVID-19 pandemic. The Rheumatoid Arthritis Disease Activity Index (RADAI) is a user-friendly tool, fully self-administered, to assess rheumatoid arthritis (RA) disease activity. The aim of this study was to compare the performance of RADAI with other disease activity indices, functional status, and inflammatory markers in a large cohort of RA patients. Methods: We assessed the concurrent validity of RADAI against Clinical Disease Activity Index (CDAI), Disease Activity Score in 28 Joints-C-reactive protein, Disease Activity Score in 28 Joints-erythrocyte sedimentation rate, Simplified Disease Activity Index, and physician assessment of disease activity and the correlation of RADAI with Health Assessment Questionnaire-Disability Index and inflammatory markers at the REAL Study baseline. We also evaluated the correlation of the change in RADAI and the change in CDAI over a 6-month follow-up. Results: From the 1115 patients included in the REAL Study, 1113 had RADAI scores in the first assessment. At baseline, correlations between RADAI and other disease activity indices were strong, ranging from 0.64 (comparison with physician assessment) to 0.79 (comparison with CDAI). Correlation between the change in RADAI score over the 6 months of follow-up and the change in CDAI score over the same period was moderate/strong for the overall group and within the stratified analyses. Conclusion: The strong correlation of RADAI with other well-established tools for disease activity measurement reassures its use with RA patients' follow-up, especially in this new era of telemedicine. Competing Interests: A.B.V.-S. has received personal fees and/or nonfinancial support from Abbvie, Janssen, and Novartis. E.S.F.C. has received speaking fees from Abbvie and is partially supported by the National Council of Scientific and Technological Development (CNPq in the Portuguese acronym, grant number 307045/2016-1). L.M.H.M. has received personal or institutional support from Abbvie, Janssen, Pfizer, and Roche, has delivered speeches at events related to this work, and was sponsored by AbbVie, Boehringer Ingelheim, GSK, Janssen, Libbs, Lilly, Novartis, Pfizer, Roche, Sandoz, and UCB. M.F.B.R.G. has received personal fees and/or nonfinancial support from Abbvie, Bristol Myers Squibb, Janssen, Novartis, Pfizer, Roche, and UCB. K.R.B. has received personal fees and/or nonfinancial support from Abbvie, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Novartis, and Roche. N.C.S. has received personal fees and/or nonfinancial support from Janssen. S.C.R. has received consulting fees, speaking fees, and institutional supporting for clinical trials from AbbVie, Amgen, Bristol Myers Squibb, Lilly, Pfizer, and Roche. I.A.P. has received personal fees and/or nonfinancial support from Abbvie, Janssen, Novartis, Roche, and UCB. C.V.B. has received personal fees and/or nonfinancial support from Abbvie, Bristol Myers Squibb, Janssen, Novartis, Pfizer, Roche, and UCB. The other authors declare no conflict of interest. (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu